Medicare’s Negotiated Drug Prices: What the IRA Actually Changed for 2026 and 2027
The government negotiating drug prices directly with pharmaceutical companies sounds like it should be simple: lower prices, lower costs, done. The reality is more nuanced — and understanding it actually matters for how you think about your own Part D coverage. Here’s the full breakdown, including the complete list of drugs affected and the real debate around whether this program is even necessary.
Key Takeaways
- The first round of negotiated prices took effect January 1, 2026, covering 10 high-spending drugs with discounts ranging from 38% to 79% off list price.
- A second round of 15 more drugs — including Ozempic, Wegovy, and Rybelsus — takes effect January 1, 2027, with discounts ranging from 38% to 85%.
- CMS calls these negotiated prices “Maximum Fair Prices” — the term you’ll see on official plan documents and formularies going forward.
- A negotiated price is not the same as what you pay at the pharmacy. It’s what Medicare pays the manufacturer — your actual out-of-pocket cost still depends on your specific plan’s deductible, tier placement, and where you are in your coverage year.
- There’s a genuine, active policy debate about whether this program is even necessary now that a hard $2,100 (2026) / $2,400 (2027) out-of-pocket cap already limits what any individual pays — we lay out both sides below.
- The program has survived multiple legal challenges from drug manufacturers so far, though litigation is ongoing.
The First Round: 10 Drugs, Effective 2026
These are the first drugs in Medicare’s history to have their prices directly negotiated between the government and the manufacturer, under authority created by the Inflation Reduction Act of 2022.

| Drug | Condition Treated | Old List Price (30-day) | Negotiated Price (2026) | Discount |
|---|---|---|---|---|
| Eliquis | Blood clots, stroke prevention | $521 | $231 | 56% |
| Xarelto | Blood clots | $517 | $197 | 62% |
| Jardiance | Diabetes, heart failure | $573 | $197 | 66% |
| Januvia | Diabetes | $527 | $113 | 79% |
| Farxiga | Diabetes, heart failure | — | — | 38–79% range |
| Entresto | Heart failure | — | — | 38–79% range |
| Enbrel | Arthritis, psoriasis | — | — | 38–79% range |
| Imbruvica | Blood cancers | — | — | 38–79% range |
| Stelara | Psoriasis, Crohn’s disease | — | — | 38–79% range |
| Fiasp / NovoLog | Insulin, diabetes | — | — | 38–79% range |
Exact negotiated prices for the remaining six drugs weren’t published with the same specificity in our research for this piece — CMS’s official fact sheet has the complete figures if you’re looking for an exact number on a specific medication.
A quick terminology note: CMS officially calls these negotiated figures Maximum Fair Prices (MFP). If you see that term on a plan document, formulary, or explanation of benefits, that’s what it’s referring to — it’s the ceiling price Medicare pays the manufacturer, not a guarantee of what you’ll personally be charged.
What This Means in Real Annual Dollars
Percentages are useful, but annual totals make the impact easier to feel. Based on the difference between old list prices and the new negotiated prices, a beneficiary taking these medications consistently for a full year could see their underlying drug cost drop by roughly:
- Eliquis: up to $3,480 per year
- Januvia: up to $4,968 per year
- Jardiance: up to $4,512 per year
To be clear, these are reductions in the underlying drug cost the system absorbs — not necessarily a dollar-for-dollar drop in your personal copay, for the reasons explained above.
Paul’s Honest Take: A client asked me last month why her Eliquis copay didn’t drop by anywhere near 56% at the pharmacy counter. That’s the single most common confusion I run into with this program — the negotiated price is what Medicare pays the manufacturer, not automatically what you pay. Your actual cost still runs through your specific plan’s deductible and cost-sharing tiers. The savings are real at the system level, but they don’t always show up dollar-for-dollar on your individual receipt.
The Second Round: 15 Drugs, Effective 2027
This round is significantly larger in scope, and includes some of the most widely used and talked-about medications in the country.
| Drug | Condition Treated |
|---|---|
| Ozempic, Rybelsus, Wegovy | Type 2 diabetes, obesity |
| Trelegy Ellipta | Asthma, COPD |
| Breo Ellipta | Asthma, COPD |
| Xtandi | Prostate cancer |
| Pomalyst | Multiple myeloma |
| Ibrance | Breast cancer |
| Ofev | Pulmonary fibrosis |
| Calquence | Leukemia, lymphoma |
| Linzess | Chronic constipation, IBS |
| Xifaxan | Hepatic encephalopathy, IBS |
| Austedo, Austedo XR | Huntington’s disease |
| Vraylar | Bipolar disorder, schizophrenia |
| Tradjenta | Type 2 diabetes |
| Janumet, Janumet XR | Type 2 diabetes |
| Otezla | Psoriasis, psoriatic arthritis |
A few specific, confirmed figures from this round: Ozempic, Wegovy, and Rybelsus are getting a 71% discount, bringing the price down to roughly $274 from a list price around $1,000. Janumet is seeing an 85% discount — the largest in this round. Austedo is seeing the smallest cut in this group, at 38%. Overall, CMS projects this round will save Medicare about $12 billion and save Part D enrollees roughly $685 million in out-of-pocket costs in 2027.
Don’t Confuse This With the GLP-1 Bridge Program
If you’ve read our guide to Medicare Part D or our deep dive on the Medicare GLP-1 Bridge Program, you may already know about this separate initiative, which covers certain GLP-1 medications for a flat $50 monthly copay. That’s a genuinely different mechanism from what’s described here, in a few important ways:
- Different pricing structure. The Bridge program’s $50 copay is a flat rate that doesn’t count toward your deductible or out-of-pocket cap. The $274 figure above is the new Maximum Fair Price the negotiation program established for 2027 — a different number, under a different program.
- Different drug list. The negotiated price applies specifically to Ozempic, Wegovy, and Rybelsus (all Novo Nordisk semaglutide products). The Bridge program’s coverage list also includes Zepbound, a competing drug from Eli Lilly — which isn’t part of this negotiation round at all.
- Different eligibility. The Bridge program has specific medical qualifying criteria and runs only through December 31, 2027 as a temporary CMS pilot. The negotiated price applies more broadly to anyone covered under standard Part D.
Depending on your specific plan and eligibility, one or neither of these could apply to you — see our full breakdown of what happens when the Bridge program ends if you’re currently relying on it. This is exactly why it’s worth confirming your actual expected cost with an agent rather than assuming either number applies automatically.
Paul’s Honest Take: The Ozempic and Wegovy news is the one I’ve gotten the most calls about, understandably. $274 is still real money, but it’s a massive drop from list price — and it’s a good example of how these negotiations tend to hit hardest on the newest, most expensive brand-name drugs, which is exactly where a lot of people are feeling the most financial pressure right now.
Is This Program Even Necessary? The Real Debate
Here’s a genuinely fair question worth asking directly: if the Inflation Reduction Act already created a hard annual out-of-pocket cap on prescription drug costs ($2,100 in 2026, rising to $2,400 in 2027), does negotiating the underlying price even matter to you personally? After all, once you hit that cap, you pay $0 regardless of the drug’s price.
The honest answer is that these two provisions work together rather than one making the other redundant:
| Without Price Negotiation | With Price Negotiation | |
|---|---|---|
| Who pays above the cap? | Once you hit your out-of-pocket cap, insurance plans and the government absorb 100% of the remaining cost at the drug’s full, uncapped price | The underlying price is lower to begin with, sharply reducing what plans and Medicare have to absorb |
| Impact on your premiums | Insurers absorbing high uncapped costs would likely raise everyone’s monthly premiums to cover it, or exit the market | Lower negotiated prices reduce that pressure, helping keep premiums more stable system-wide |
In other words, the out-of-pocket cap protects you directly and immediately. Price negotiation protects the system underneath that cap — and by extension, your premiums — from absorbing runaway costs indefinitely.
The Case For the Program
Supporters — including CMS, the Medicare Rights Center, and various senior advocacy groups — point to a few core arguments:
- System-wide savings. The first round alone is projected to save Medicare around $6 billion annually, helping the program’s long-term financial sustainability.
- Direct help even for lower-spending patients. Not everyone hits the annual out-of-pocket cap. Millions of people taking these drugs but spending less than the cap still benefit from lower copays and coinsurance on every fill.
- Premium stabilization. Advocates argue that lowering the baseline cost of these high-spending drugs takes pressure off the entire Part D market, helping prevent steeper premium increases for everyone.
The Case Against the Program
Pharmaceutical manufacturers, market analysts, and some policy groups raise different concerns:
- Potential impact on drug development. The core argument from manufacturers is that price caps could reduce the financial incentive for research and development — some companies have suggested they may deprioritize secondary uses for existing drugs or higher-risk clinical trials as a result.
- Legal and operational challenges. The program has faced multiple lawsuits from drug manufacturers challenging its constitutionality. CMS has continued implementation while litigation proceeds, and the administrative systems supporting the program are still relatively new.
Paul’s Honest Take: I’m not going to pretend to have a strong opinion on the R&D innovation debate — that’s a genuinely complicated economic question that reasonable people disagree on, and it’s above my pay grade as a Medicare broker. What I can tell you plainly is what I see on the ground: clients on these specific medications are generally paying less than they were, and that’s a real, tangible benefit regardless of how the broader policy debate eventually settles.
What This Means for You, Practically
- Check whether your medications are on either list. If you’re taking Eliquis, Jardiance, Ozempic, or any of the other drugs above, your actual cost may already be lower — or will be, starting in 2027.
- Don’t assume the negotiated price equals your copay. Your specific plan’s formulary tier and where you are in your deductible still determine what you actually pay at the counter.
- This is exactly the kind of thing worth checking during AEP. Formularies and tier placements shift every year — a plan that had your drug at a high tier last year may have adjusted following these price changes.
Frequently Asked Questions
Does a lower negotiated price mean my copay automatically drops? Not necessarily. The negotiated price is what Medicare pays the manufacturer. Your actual out-of-pocket cost depends on your specific Part D plan’s deductible, formulary tier, and cost-sharing structure.
How were these specific drugs chosen? CMS selects drugs based on total Medicare Part D spending and enrollment — essentially, the highest-cost, most-used brand-name drugs without generic competition are prioritized first.
Will more drugs be negotiated in future years? Yes. The law calls for 15 more drugs in 2028, and 20 additional drugs each year after that, gradually expanding the program’s scope.
Is this program at risk of being reversed? It’s been the subject of ongoing lawsuits from drug manufacturers, but CMS has continued implementation through both the Biden and Trump administrations to date. As with any federal program tied to litigation, it’s worth watching for updates rather than assuming its future is fully settled.
I’m on one of these drugs — should I switch plans because of this? Not automatically. This is exactly the kind of specific, personal question worth reviewing with an agent during AEP — your actual cost depends on your specific plan’s structure, not just the drug’s negotiated price.
Is the $274 Ozempic price the same as the GLP-1 Bridge program’s $50 copay? No — these are two separate programs with different pricing, different eligibility rules, and even a different drug list (the Bridge program also covers Zepbound, which isn’t part of this negotiation round). The $274 figure is the new Maximum Fair Price Medicare negotiated with the manufacturer for 2027. Which one (or neither) applies to you depends on your specific plan and eligibility — see our full Bridge program breakdown or confirm directly with an agent.
The Bottom Line
Medicare negotiating drug prices directly is a genuinely significant shift, and the two rounds so far are delivering real, substantial discounts — some over 70%. But a lower negotiated price and a lower personal copay aren’t automatically the same thing, and the honest answer to “is this program still needed given the out-of-pocket cap” is that the two provisions are doing different jobs, not competing with each other.
If you’re on any of the medications listed above, or just want to understand how this actually affects your specific plan and costs, that’s exactly the kind of conversation worth having before this year’s Annual Enrollment Period.
Call 631-358-5793 or visit paulbinsurance.com to talk through your specific situation.
Paul Barrett, CMIP, is the founder of The Modern Medicare Agency, based in Melville, NY, and has spent 18+ years exclusively helping people navigate Medicare — never life insurance, never annuities, just Medicare. He’s licensed in 37 states, represents more than 40 carriers, and has personally helped over 5,000 clients choose coverage that actually fits their lives.
Figures current as of 2026 and sourced from CMS and independent reporting on the Medicare Drug Price Negotiation Program. Individual costs vary by plan, formulary tier, and coverage stage — always verify your specific situation before making enrollment decisions.





